Chudova Darya, Chief Technology Officer at Guardant Health (GH), has demonstrated a clear selling bias in her recent insider transactions, with $5.35 million in total sales outweighing $58,308 in purchases across 27 filings. Her activity has been exclusively concentrated in GH, with no trades in other companies. The most significant disposals occurred in late 2025 and early 2026, including three sales totaling $2.99 million between December 8 and December 15, 2025, followed by a $1.26 million transaction on January 1, 2026, and a $492,336 sale on March 15, 2026. These disposals dwarf her limited acquisition activity, which consisted of a single $58,308 purchase on January 16, 2024, and smaller transactions under $80,000 in 2024-2025.
The pattern shows acceleration in selling volume since late 2025, with all three most recent transactions being disposals. While some filings represent option exercises or awards (coded M, F, A), the monetization events (coded S) dominate the value. Notably, the March 2026 sales followed a cluster of awards and option-related activity earlier that month, suggesting Darya may be systematically liquidating vested positions. The absence of any buys since early 2024 reinforces the one-directional nature of her recent trading behavior in GH stock.
AI-assisted summary